Isu Abxis Obtains European Patent for Hemophilia New Drug from US Partner 'Catalyst'

[Asia Economy Reporter Oh Ju-yeon] ISU Abxis announced on the 6th that Catalyst Biosciences, its development partner for the subcutaneous injection type hemophilia B treatment new drug 'DalcA,' recently received a patent decision from the European Patent Office.

Nasim Usman, CEO of Catalyst, said, "This European patent decision secures intellectual property rights for DalcA (Dalcinonacog Alfa, project name: ISU304/CB2679d) following the United States, China, and Japan, expanding the scope of our portfolio," adding, "Recently, DalcA completed Phase 2b clinical trials, and we believe DalcA is an appropriate strategy for treating hemophilia B."

Designated as an orphan drug for DalcA by the European Commission in June 2017, Catalyst announced interim results of the Phase 2 clinical trial at the European Association for Haemophilia and Allied Disorders (EAHAD) in February.

Subsequently, last month, Catalyst completed the Phase 2b clinical trial of DalcA, the next-generation subcutaneous injection type Factor IX (FIX; coagulation factor IX). Catalyst plans to announce the final clinical data within the first half of this year.

This content was produced with the assistance of AI translation services.